Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMFGQXB)

• Drug Name: CD28 and CD137 CAR-T Cells Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Acute lymphoblastic leukaemia	2A85	Phase 1	[1]

• Cross-matching ID: TTD Drug ID: DMFGQXB

Molecule-Related Drug Atlas

Drug(s) Targeting T-cell-specific surface glycoprotein CD28 (CD28)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Belatacept	DMXLYQF	Kidney transplant rejection	NE84	Approved	[2]
AB-103	DMPDQ8T	Necrotizing soft tissue infection	1B71	Phase 3	[3]
Lulizumab pegol	DMGWZ93	Systemic lupus erythematosus	4A40.0	Phase 2	[4]
REGN5678	DM0Y6WU	Prostate cancer	2C82.0	Phase 1/2	[5]
AU101	DMLAKPI	Osteosarcoma	2B51	Phase 1/2	[6]
REGN5668	DMH1UV5	Ovarian cancer	2C73	Phase 1/2	[7]
SAR442257	DMXD5QP	Malignant neoplasm	2A00-2F9Z	Phase 1	[8]
CD19-CAR and CD28-CAR T Cells	DMUR1MN	Acute lymphoblastic leukaemia	2A85	Phase 1	[9]
RO7443904	DMSWZNU	Non-hodgkin lymphoma	2B33.5	Phase 1	[10]
RG6333	DM1BRF2	Non-hodgkin lymphoma	2B33.5	Phase 1	[11]

Drug(s) Targeting Co-stimulatory molecule 4-1BB (CD137)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Urelumab	DM6RTVG	B-cell non-hodgkin lymphoma	2B33.5	Phase 2	[6]
Anti-CD137	DMHVZ27	Solid tumour/cancer	2A00-2F9Z	Phase 2	[12]
MG7-CART	DME6PB0	Acute myeloid leukaemia	2A60	Phase 1/2	[13]
NM21-1480	DMDNJP5	Advanced solid tumour	2A00-2F9Z	Phase 1/2	[14]
CD137 CAR-T Cell	DMHMC19	Acute lymphoblastic leukaemia	2A85	Phase 1/2	[15]
ADG106	DM87H0S	Non-hodgkin lymphoma	2B33.5	Phase 1/2	[16]
MCLA-145	DM8CGUV	Lymphoma	2A80-2A86	Phase 1	[17]
GEN1046	DMEWRNZ	Solid tumour/cancer	2A00-2F9Z	Phase 1	[18]
INBRX-105	DM2FH10	Solid tumour/cancer	2A00-2F9Z	Phase 1	[19]
GEN1042	DMNP6T3	Solid tumour/cancer	2A00-2F9Z	Phase 1	[18]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Co-stimulatory molecule 4-1BB (CD137)	TTPW9LJ	TNR9_HUMAN	CAR-T-Cell-Therapy(Dual specific)	[1]
T-cell-specific surface glycoprotein CD28 (CD28)	TTQ13FT	CD28_HUMAN	CAR-T-Cell-Therapy(Dual specific)	[1]

References

• [1] ClinicalTrials.gov (NCT02186860) Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy in Treating Patients With Acute Lymphoblastic Leukemia
• [2] New developments in immunosuppressive therapy for heart transplantation. Expert Opin Emerg Drugs. 2009 Mar;14(1):1-21.
• [3] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [4] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [5] Clinical pipeline report, company report or official report of Regeneron Pharmaceuticals.
• [6] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [7] ClinicalTrials.gov (NCT04590326) Phase 1/2 Study of REGN5668 (MUC16xCD28, a Costimulatory Bispecific) Administered in Combination With Cemiplimab or REGN4018 (MUC16xCD3). U.S.National Institutes of Health.
• [8] Clinical pipeline report, company report or official report of Sanofi.
• [9] ClinicalTrials.gov (NCT02146924) Cellular Immunotherapy in Treating Patients With High-Risk Acute Lymphoblastic Leukemia
• [10] Clinical pipeline report, company report or official report of Genentch
• [11] Clinical pipeline report, company report or official report of Roche
• [12] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1878).
• [13] ClinicalTrials.gov (NCT02862704) A Study of MG7 Redirected Autologous T Cells for Advanced MG7 Positive Liver Metastases(MG7-CART)
• [14] Clinical pipeline report, company report or official report of Numab Therapeutics.
• [15] ClinicalTrials.gov (NCT02965092) CD19 Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy in Treating Patients With B-cell Malignancies
• [16] Clinical pipeline report, company report or official report of Adagene.
• [17] Clinical pipeline report, company report or official report of Merus.
• [18] Clinical pipeline report, company report or official report of Genmab.
• [19] Clinical pipeline report, company report or official report of Inhibrx.